GlassScriptPhysician profile
Bethany B Lamar
NPI 1467494914
$2,061.03
in general payments reported to CMS, 2019-2025
30 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $853 · 2022: $242 · 2023: $264 · 2024: $371 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.41 | 2021-2025 | |
| Novo Nordisk INC | $252.38 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $193.99 | 2021-2024 | Airsupra |
| Pfizer INC. | $164.48 | 2021-2024 | |
| Astellas Pharma US INC | $121.43 | 2021-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $108.74 | 2022-2025 | |
| Corcept Therapeutics | $100.68 | 2021-2025 | Korlym |
| Glaxosmithkline, LLC. | $75.65 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $71.56 | 2021-2024 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $70.88 | 2025 | Recorlev |
| E.R. Squibb & Sons, L.L.C. | $62.23 | 2021-2023 | Eliquis |
| Csl Behring | $60.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.07 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.14 | 2022-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $29.72 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $25.81 | 2021 | |
| Lilly USA, LLC | $24.82 | 2025 | Mounjaro |
| Medicomp INC | $23.23 | 2024 | Telepatch Cardiac Monitor |
| Insulet Corporation | $21.43 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.79 | 2022 | |
| Mannkind Corporation | $20.23 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.77 | 2025 | |
| Halozyme INC | $18.22 | 2023 | |
| Insmed, INC. | $17.27 | 2025 | Arikayce |
| Emmaus Medical, INC. | $15.26 | 2021 | |
| Medtronic, INC. | $15.09 | 2025 | Minimed 780g |
| Exact Sciences Corporation | $14.49 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $14.46 | 2022 | |
| Laborie Medical Technologies Corp. | $13.05 | 2022 | |
| Radius Health, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Lamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.